AllTrials: will it catch on in the US?
This article was originally published in SRA
Executive Summary
News that the AllTrials campaign has been launched in the US will be welcomed by transparency advocates. But it will be viewed with great disquiet by those in the pharmaceutical industry and elsewhere who are open to a degree of greater clinical trial disclosure but draw the line at releasing patient-level data.
You may also be interested in...
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.